Related Experiment Video
Updated: Sep 20, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era
Maria Gion1,2, Dario Trapani3,4, Alfonso Cortés1,2
1Medical Oncology Department, Ramóny Cajal University Hospital, Madrid, Spain.
Abstract:
Patients with HER2-positive breast cancer account for approximately 15% to 20% of all breast cancers and represent one of the most aggressive breast cancer subtypes. Survival rates of patients with metastatic disease have improved dramatically and progressively. Many new agents have been developed, and long-term follow-up from trials of anti-HER2 agents has shown long-term responses. The availability of novel, highly active anti-HER2 treatments, together with the ongoing development of promising diagnostic tools, will offer the unprecedented opportunity to raise cure rates. Our ultimate goal is to tailor treatment intensity to disease and patient characteristics, hopefully increasing the fraction of cured patients while minimizing the risk for overtreatment. If conducted rationally and carefully, this plan has the potential to break a decades-long paradigm, leading to a new, precise era of treatment of HER2-positive breast cancer.
Insights
New anti-HER2 treatments and diagnostic tools offer hope for curing HER2-positive breast cancer. Personalized treatment strategies aim to increase cure rates while minimizing overtreatment for this aggressive cancer subtype.
Area of Science:
- Oncology
- Cancer Research
- Medical Therapeutics
Background:
- HER2-positive breast cancer constitutes 15-20% of all breast cancers.
- This subtype is recognized as one of the most aggressive forms of breast cancer.
- Recent advancements have significantly improved survival rates for patients with metastatic disease.
Purpose of the Study:
- To highlight the impact of novel anti-HER2 agents on patient survival.
- To discuss the potential of new diagnostic tools in conjunction with treatments.
- To propose a paradigm shift towards personalized treatment strategies for HER2-positive breast cancer.
Main Methods:
- Review of long-term follow-up data from clinical trials of anti-HER2 agents.
- Analysis of the efficacy of novel therapeutic agents.
- Evaluation of emerging diagnostic technologies for HER2-positive breast cancer.
Main Results:
- Long-term responses observed in patients treated with anti-HER2 agents.
- Significant improvements in survival rates for metastatic HER2-positive breast cancer.
- Development of novel, highly active anti-HER2 treatments.
Conclusions:
- Novel anti-HER2 treatments and diagnostic tools present an opportunity to increase cure rates.
- Tailoring treatment intensity based on individual patient and disease characteristics is crucial.
- A precise, personalized approach has the potential to redefine the treatment of HER2-positive breast cancer, moving beyond traditional paradigms.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...